A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis

Trial Profile

A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Tetracycline (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2012 Official title amended as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Planned End Date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 05 Dec 2011 Actual initiation date (Nov 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top